Kainos HIV Candidate Leaps Ahead In China Under Priority Review
Executive Summary
Kainos Medicine's HIV drug candidate KM-023 is set to move directly into a Phase III program in China through local licensee Jiangsu Aidea, benefiting from the country's fast-track review system and accelerating the development of the drug, which Kainos sees as bringing multiple possible benefits over existing therapies.